Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca moves finance chief to new role after Alexion deal

Published 06/04/2021, 02:08 AM
Updated 06/04/2021, 05:40 AM
© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble

© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble

By Pushkala Aripaka

(Reuters) - AstraZeneca (NASDAQ:AZN) will move finance chief Marc Dunoyer to head newly acquired rare diseases business Alexion (NASDAQ:ALXN), using the $39 billion takeover as an opportunity to freshen up a management team that had been in place for eight years.

Chief Executive Pascal Soriot has faced heavy public criticism and EU legal action after AstraZeneca missed targets for coronavirus vaccine deliveries, with he and Dunoyer also attracting investor anger over their pay packages last month.

Dunoyer will replace Ludwig Hantson as boss of United States-based Alexion on completion of the agreed deal, with the proposed switch allowing Aradhana Sarin to move in the opposite direction and become AstraZeneca chief financial officer.

The Anglo-Swedish drugmaker agreed in December to buy Alexion in a bet on rare-disease immunology to add to its fast-growing cancer medicines unit and a major COVID-19 vaccine.

London-listed AstraZeneca said Sarin's appointment is also conditional upon completion of the Alexion deal, which was approved by shareholders last month. Britain and the European Union are reviewing the deal, which gained U.S. approval in April.

As well as becoming Alexion chief executive, Dunoyer will also be appointed chief strategy officer at AstraZeneca. He will leave the board but continue to report to Soriot.

Soriot and Chairman Leif Johansson have been in their roles since 2012 and Dunoyer was appointed in late 2013 https:// In an interview with the Financial Times last month https://on.ft.com/3zapoJp, Soriot indicated that succession planning had begun for the three men at the top.

SHAKE-UPS

India-born Sarin would become the first woman to take up the CFO role at AstraZeneca on a permanent basis. She joins a handful of women in the so-called C-Suite of top executives at UK blue-chip companies.

Sarin's addition to the board increases the composition of female board members to 42% from 33%, Barclays (LON:BARC) analysts said in a note.

"In Aradhana Sarin, we've appointed a talented successor to Marc," AstraZeneca's Johansson said in a statement.

It was unclear what role Alexion's Hantson will take after Dunoyer's arrival. Hantson did not immediately respond to a request for comment via networking platform LinkedIn.

AstraZeneca declined to comment and a representative for Alexion could not be reached for comment outside business hours.

Hantson joined Alexion in 2017, as did Sarin and former AstraZeneca CEO David Brennan, to regain investor confidence after its top executives left amid an internal investigation over sales of Alexion's top-selling drug, Soliris.

© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble

Soliris is used against a range of rare immune-disorders, and AstraZeneca hopes that an improved version of the drug will boost sales further.

($1 = 0.7098 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.